Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.

“We are excited for the opportunity to present at a premier gastroenterology event like ACG and share additional findings from our Phase 1b study of NX-13 in patients with UC,” said Gregory Oakes, President and CEO of Landos. “The presentations cover the rapid symptomatic relief and improvements in multiple biomarkers, correlating with early endoscopic response of NX-13 in patients with moderate-to-severe UC. The data highlight the potential of NX-13 to transform the standard of care in moderate-to-severe UC with an oral, once-daily treatment, and further our confidence in the ongoing NEXUS proof-of-concept trial.”

The Company continues to actively recruit, screen and randomize patients for the NEXUS trial, with topline results expected by the fourth quarter of 2024.

Presentation Details

Title: The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 Demonstrates Rapid Symptomatic and Biomarkers Improvement in Ulcerative Colitis: Results In a Phase 1b Study (00997)
Scientific Poster Session: P3607
Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT

Title: Rapid Symptomatic Relief Is Correlated with Early Endoscopic Response to the Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 In Ulcerative Colitis: Results in a Phase 1b Study (00995)
Scientific Poster Session: P3644
Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT

Title: Target Engagement and Pharmacodynamic Molecular Mechanism Evaluation In A Phase 1b Study of The Nucleotide-Binding Oligomerization Domain, Leucine Rich Repeat Containing X1 (NLRX1) Agonist NX-13 in Ulcerative Colitis (00958)
Scientific Poster Session: P3548
Date & Time: Tuesday, October 24, 2023 at 10:30am - 4:00pm PDT

About Landos Biopharma

Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune diseases. Our mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm.